论文部分内容阅读
目的研究血管内皮生长因子(VEGF)、凝血酶敏感蛋白1(TSP-1)在膀胱移行细胞癌的表达及其与肿瘤分级、分期和复发的关系,探讨VEGF、TSP-1在肿瘤血管形成过程中的相互关系及肿瘤新的血管生成的分子机制。方法以免疫组化法检测69例膀胱移行细胞癌以及正常膀胱组织10例标本中VEGF、TSP-1表达及微血管密度,用免疫印迹实验方法来检测组织VEGF、TSP-1蛋白的表达情况。结果 (1)膀胱移行细胞癌中VEGF表达及MVD均明显高于正常膀胱组织(P<0.05),TSP-1表达低于正常膀胱组织(P<0.05);(2)膀胱移行细胞癌组织中,VEGF表达及MVD随临床分期及组织学分级的增加而增加(P<0.05),TSP-1表达随分级和分期的进展而降低(P<0.05);(3)膀胱移行细胞癌组织中TSP-1与VEGF蛋白表达强度呈显著负相关关系(r=-0.356,P<0.05);(4)膀胱肿瘤的发生、发展与VEGF蛋白的过高表达和TSP-1的过低表达密切相关。结论 VEGF与TSP-1可能成为估计膀胱移行细胞癌恶性程度及肿瘤侵袭性的一项有用的指标,VEGF与TSP-1的表达可能起互相调节作用。
Objective To investigate the expression of vascular endothelial growth factor (VEGF) and thrombospondin-1 (TSP-1) in bladder transitional cell carcinoma and its relationship with tumor grade, stage and recurrence, and to explore the role of VEGF and TSP-1 in tumor angiogenesis In the relationship between tumor and new molecular mechanisms of angiogenesis. Methods Immunohistochemistry was used to detect the expression of VEGF, TSP-1 and microvessel density in 69 cases of transitional cell carcinoma of the bladder and 10 cases of normal bladder tissues. The expression of VEGF and TSP-1 protein were detected by Western blotting. Results (1) The expression of VEGF and MVD in bladder transitional cell carcinoma were significantly higher than those in normal bladder tissue (P <0.05), and the expression of TSP-1 was lower in bladder transitional cell carcinoma (P <0.05). (2) , VEGF expression and MVD increased with the increase of clinical stage and histological grade (P <0.05). The expression of TSP-1 was decreased with the progress of grading and staging (P <0.05). (3) The expression of TSP in bladder transitional cell carcinoma (R = -0.356, P <0.05). (4) The occurrence and development of bladder tumor are closely related to the overexpression of VEGF protein and the overexpression of TSP-1. Conclusions VEGF and TSP-1 may be useful indicators for estimating the malignancy and invasiveness of bladder transitional cell carcinoma. The expression of VEGF and TSP-1 may play an important role in the regulation of bladder transitional cell carcinoma.